| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 10 | 20 | 30 | 30 | 100 |
| Sales Growth | -50.00% | -33.33% | unch | -70.00% | unch |
| Net Income | -910 | -3,690 | -3,600 | -1,580 | -3,740 |
| Net Income Growth | +75.34% | -2.50% | -127.85% | +57.75% | -50.20% |
Boston Therapeutics (BTHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Boston Therapeutics, Inc. is a pharmaceutical company engaged in the development, manufacturing, and commercialization of compounds for the treatment of diabetes and inflammatory diseases. The Company focuses on glyco-pathology. Its product portfolio includes SUGARDOWN(R), PAZ320 and IPOXYN(TM). Boston Therapeutics, Inc. is based in Manchester, New Hampshire.